William Blair believes investors could view Viking Therapeutics (VKTX)’ multi-year manufacturing pact with CordenPharma as a negative to Viking’s takeover prospects. Nonetheless, the analyst is “enthusiastic” about the Corden agreement and believes the “breadth and the depth” of the pact significantly reduce the supply chain risk following potential commercialization of VK2735. This had been an overhang on the stock, the analyst tells investors in a research note. Blair keeps an Outperform rating on Viking Therapeutics. The stock in early trading is down 8% to $25.79.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Strategic Manufacturing Deal Boosts Viking Therapeutics’ Stock Outlook
- Viking Therapeutics signs broad manufacturing agreement with CordenPharma
- Novo Nordisk under pressure as obesity drug disappoints in diabetes trial
- H.C. Wainwright says Novo results support Viking obesity potential
- Promising Potential of Viking Therapeutics’ VK2735 in Obesity and Diabetes Treatment Drives Buy Rating
Questions or Comments about the article? Write to editor@tipranks.com